We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $19.3B
1-Year Est. Return 39.18%
This Fund
S&P 500
This Quarter Est. Return
+6.25%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$17.4B
AUM Growth
+$904M
Cap. Flow
+$84.9M
Cap. Flow %
0.49%
Top 10 Hldgs %
29.78%
Holding
722
New
36
Increased
329
Reduced
218
Closed
40

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$66.4M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$57.7M
3
AMZN icon
Amazon
AMZN
+$56.5M
4
AMD icon
Advanced Micro Devices
AMD
+$37.5M
5
CRM icon
Salesforce
CRM
+$35.5M

Top Sells

Rank Stock Value
1
LRCX icon
Lam Research
LRCX
+$122M
2
TMO icon
Thermo Fisher Scientific
TMO
+$60.8M
3
AMAT icon
Applied Materials
AMAT
+$43.7M
4
NU icon
Nu Holdings
NU
+$35.9M
5
INCY icon
Incyte
INCY
+$32.5M

Sector Composition

Rank Sector Weight
1 Technology 31.8%
2 Healthcare 28.54%
3 Financials 9.44%
4 Consumer Discretionary 7.84%
5 Industrials 7.59%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZLAB icon
276
Zai Lab
ZLAB
$2.07B
$9.41M 0.05%
390,023
+25,010
+7% +$473K
PLRX icon
277
Pliant Therapeutics
PLRX
$65M
$9.34M 0.05%
833,216
– –
PRAX icon
278
Praxis Precision Medicines
PRAX
$8.11B
$9.32M 0.05%
+162,031
New +$8.75M
SRRK icon
279
Scholar Rock
SRRK
$5.88B
$9.26M 0.05%
1,155,536
+411,093
+55% +$3.61M
NMRA icon
280
Neumora Therapeutics
NMRA
$306M
$8.93M 0.05%
+676,244
New +$7.89M
OPCH icon
281
Option Care Health
OPCH
$3.76B
$8.81M 0.05%
281,512
+43,957
+19% +$1.35M
CI icon
282
Cigna
CI
$78.4B
$8.58M 0.05%
24,762
-45,949
-65% -$15.8M
GPK icon
283
Graphic Packaging
GPK
$3.35B
$8.52M 0.05%
287,909
-276,055
-49% -$7.85M
COP icon
284
ConocoPhillips
COP
$144B
$8.5M 0.05%
80,718
+875
+1% +$96.1K
SYF icon
285
Synchrony
SYF
$24.4B
$8.42M 0.05%
168,908
-486,265
-74% -$23.5M
GMED icon
286
Globus Medical
GMED
$11.1B
$8.42M 0.05%
117,689
+40,023
+52% +$2.83M
GH icon
287
Guardant Health
GH
$19.1B
$8.4M 0.05%
366,145
– –
EW icon
288
Edwards Lifesciences
EW
$49.4B
$8.4M 0.05%
127,235
-73,090
-36% -$5.31M
TWLO icon
289
Twilio
TWLO
$28.6B
$8.28M 0.05%
127,027
-35,171
-22% -$2.1M
EA icon
290
Electronic Arts
EA
$52.4B
$8.25M 0.05%
57,501
-50,044
-47% -$7.26M
LKQ icon
291
LKQ Corp
LKQ
$6.72B
$8.11M 0.05%
203,072
+48,412
+31% +$1.99M
EHC icon
292
Encompass Health
EHC
$11.3B
$8.02M 0.05%
82,974
+20,948
+34% +$1.88M
EQR icon
293
Equity Residential
EQR
$25.8B
$8.02M 0.05%
107,674
+74,516
+225% +$5.38M
VCYT icon
294
Veracyte
VCYT
$4.45B
$7.89M 0.05%
231,676
-439,261
-65% -$12.4M
EWTX icon
295
Edgewise Therapeutics
EWTX
$4.28B
$7.86M 0.05%
294,624
-34,376
-10% -$684K
ITOS
296
DELISTED
iTeos Therapeutics
ITOS
$7.85M 0.05%
769,213
+259,910
+51% +$3.97M
RLAY icon
297
Relay Therapeutics
RLAY
$4B
$7.74M 0.04%
1,092,705
+389,276
+55% +$2.91M
SRE icon
298
Sempra
SRE
$58.1B
$7.63M 0.04%
91,223
+3,073
+3% +$246K
SRPT icon
299
Sarepta Therapeutics
SRPT
$1.64B
$7.43M 0.04%
59,508
-69,492
-54% -$9.61M
KB icon
300
KB Financial Group
KB
$39.5B
$7.36M 0.04%
4,279
– –
10 11
12
13 14

Similar funds

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
A
AustralianSuper Melbourne, Australia $19.2B AUM 31.95% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $19.4B AUM 16.7% 1-Year Est. Return
LF
Lansforsakringar Fondforvaltning Stockholm, Sweden $19.1B AUM 26.9% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
MIM
MetLife Investment Management Whippany, New Jersey $19.6B AUM 32.64% 1-Year Est. Return

Candriam SCA's Q3 2024 Portfolio in Review

As of Q3 2024, Candriam SCA held 722 positions worth $17.4B, up 5.5% from $16.5B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Candriam SCA's Q3 2024 filing shows 36 new, 329 increased, 218 reduced and 40 closed positions. Its largest new stake was Avidity Biosciences: 323,396 shares worth $14.9M. The largest sale was Lam Research, an estimated $122M.

By sector, the portfolio is most concentrated in Technology at 32% of assets, down from 33% a quarter earlier, followed by Healthcare and Financials.

  • Candriam SCA's largest Q3 2024 buy was Avidity Biosciences: 323,396 shares worth $14.9M.
  • Candriam SCA added most to Amgen in Q3 2024, an estimated $66.4M increase.
  • Candriam SCA's biggest Q3 2024 reduction was Thermo Fisher Scientific, cutting an estimated $60.8M.
  • Candriam SCA fully exited Lam Research in Q3 2024, selling an estimated $122M.
  • Candriam SCA's ten largest holdings make up 30% of its $17.4B portfolio in Q3 2024.
  • Candriam SCA opened 36 new positions and closed 40 in Q3 2024.
  • Candriam SCA's portfolio value rose 5.5% quarter-over-quarter to $17.4B.

Based on Candriam SCA's 13F filing for Q3 2024, filed 13 Nov 2024.